Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biohaven Ltd
(NY:
BHVN
)
39.75
+1.17 (+3.03%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biohaven Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
February 24, 2023
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
12 Health Care Stocks Moving In Monday's After-Market Session
February 13, 2023
Via
Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
February 02, 2023
The company that remains still has a large pipeline of non-migraine assets.
Via
Investor's Business Daily
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
January 18, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
January 24, 2023
Via
Benzinga
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
December 16, 2022
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
January 04, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
December 02, 2022
Via
Benzinga
Jim Cramer Says This Stock Is Dynamite: 'I Do Not Want You To Do A Thing Other Than Ride It'
December 01, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Williams Companies, Inc. (NYSE: WMB) is "terrific." He recommended buying the stock.
Via
Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
$41 Million Bet On This Biotechnology Stock? 3 Stocks Insiders Are Buying
October 27, 2022
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
October 24, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Via
Benzinga
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
October 24, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Intuitive Surgical, Netflix, ASML And Other Big Gainers From Wednesday
October 20, 2022
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping 100 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 18, 2022
Gainers
Via
Benzinga
Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday
October 20, 2022
Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
Upgrades
Via
Benzinga
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
October 11, 2022
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 10, 2022
Gainers
Via
Benzinga
Coinbase Global And 3 Other Stocks Insiders Are Buying
October 07, 2022
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains?
October 07, 2022
Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares...
Via
Talk Markets
Pinterest, Perion Network And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
October 06, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Why WISeKey International Is Trading Higher By Over 20%; Here Are 29 Stocks Moving Premarket
October 06, 2022
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For...
Via
Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
October 06, 2022
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 04, 2022
On Tuesday, 44 companies hit new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 04, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.
Via
Benzinga
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
October 03, 2022
From
Pfizer Inc.
Via
Business Wire
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
September 29, 2022
The drug has faced two advisory committees and a delayed review date.
Via
Investor's Business Daily
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
September 29, 2022
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).
Via
Benzinga
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
September 29, 2022
Patients didn't show any improvements in a study meant to test multiple drugs.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.